An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients



Status:Completed
Conditions:Parkinsons Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:Any
Updated:4/20/2017
Start Date:November 2004
End Date:May 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

This is an open-label extension study to assess the long-term safety and tolerability of
pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).


Inclusion Criteria-

- Patients of any age, male or female with a clinical diagnosis of idiopathic
Parkinson's disease, who participated in a previous (Phase II) clinical trial that
evaluated pimavanserin

- Patients who may, in the opinion of the treating physician, benefit from continued
therapy with pimavanserin

- Patient is willing and able to provide consent

Exclusion Criteria-

- Female patient of childbearing potential

- Patient has a clinically significant concurrent medical illness

- Patient is judged by the treating physician to be inappropriate for the study.
We found this trial at
1
site
Clinical Trial Facility in Danbury Connecticut
Danbury, Connecticut 06810
?
mi
from
Danbury, CT
Click here to add this to my saved trials